|
1) Dustan HP. History of clinical hypertension:
from 1982 to 1970. In: Oparil S, Weber MA, editors. Hypertension: a
companion to Brenner and Rector's the kidney. Philadelphia: WS Saunders
Company; 2000.p.1-19.
2) Kannel WB. Risk factors in hypertension.
J Cardiovasc Pharmacol 1989; 13(Suppl 1): S4-10.
3) Futterman LG, Lemberg L. The Framingham
Heart Study: a pivotal legacy of the last millennium. Am J Cit Care
2000; 9: 147-51.
4) Kannel WB. Fifty year of Framingham
study contri-butions to understanding hypertension. J Hum Hyper-tens
2000; 14: 83-90.
5) Kannel WB. The Framingham study: its
50-year legacy and future promise. J Atheroscler Thromb 2000; 6: 60-6.
6) D'Agostino RB, Russell MW, Huse DM,
Ellison RC, Silbershatz H, Wilson PWF, et al. Primary and coronary appraisal:new
results from the Framingham Study. Am Heart J 2000; 139: 272-81.
7) Dawber TR, Kannel WB, Revotskie N,
Stokes J �｡, Kagan A, Gordon T. Some factors associated with the development
of coronary heart disease: six years' follow-up experience in the Framingham
study. Am J Pub Health 1959; 49: 1349-56.
8) Truett J, Cornfield J, Kannel W. Amultivariate
analysis of the risk of coronary heart disease in Framingham. J Chronic
Dis 1967; 20: 511-24.
9) Anderson KM, Odell PM, Wilson PWF,
Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:
293-8.
10) Myers RH, Kiely DK, Cupples LA, Kannel
WB. Parental history is an independent risk factor for coronary heart
disease: the Framingham Study. Am Heart J 1990; 120: 963-9.
11) Franklin SS, Gustin W, Wong ND, Larson
MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related
changes in blood pressure:the Framingham Study. Circulation 1997; 96:
308-15.
12) Kannel WB, Garrison RJ, Dannenberg
AL. Secular blood pressure trends in normotensive persons: the Framin-gham
Study. Am Heart J 1993; 125: 1154-8.
13) Kannel WB. Hypertension and the risk
of cardiovascular disease. In: Laragh JH, Brenner BM, editors. Hyperten-sion:
pathology, diagnosis, and management. New York: Raven Press; 1990. p.101-7.
14) Tell GS, Rutan GH, Kronmal RA, Bild
DE, Polak JF, Wong ND, et al. For the Cardiovascular Health Study (CHS)
Collaborative Research Group: correlates of blood pressure in community-dwelling
older adults: the Cardiovascular Health Study. Hypertension 1994; 23:
59-67.
15) Franklin SS. Ageing and hypertension:
the assessment of blood pressure induces in predicting coronary heart
disease. J Hypertens 1999; 17(Suppl 5): S29-36.
16) Sagie A, Larson MG, Levy D. The natural
history of borderline isolated systolic hypertension. N Engl J Med 1993;
329: 1912-7.
17) Franklin SS, Jacobs MJ, Wong ND,
L'Iyalien GJ, Lapuerta P. Predominance of isolated systolic hyper-tension
among middle-aged and elderly US hypereten-sives: analysis based on
National Health and Nutrition Examination Survey（NHANES）III. Hypertension
2001; 37: 869-74.
18) Kannel WB. Elevated systolic blood
pressure as a cardiovascular risk factor. Am J Cardiol 2000; 85: 251-5.
19) Vokonas PS, Kannel WB, Cupples LA.
Epidemiology and riak of hypertension: the Framingham Study. J Hyper-tens
1988; 6(Suppl 1): S3-9.
20) Kannel WB. Histolic perspectives
on the relative contributions of diastolic and systolic blood pressure
elevation to cardiovascular risk profile. Am Heart J 1999; 138(3 part
2): S205-10.
21) Kannel WB, Dawber TR, McGee DL. Perspectives
on systolic hypertension: the Framingham Study. Circula-tion 1980; 61:
1179-82.
22) Franklin SS, Larson MG, Khan SA,
Wong ND, Leip EP, Kannel WB, et al. Does the relation of blood pressure
to coronary heart disease risk change with aging?: the Framingham Heart
Study. Circulation 2001; 103: 1245-9.
23) Franklin SS, Kahn SA, Wong ND, Larson
MG, Levy D. Is pulse pressure useful in predicting risk for coronary
heart disease?: the Framingham Heart Study. Circula-tion 1999; 100:
354-60.
24) Benetos A, Thomas F, Safar ME, Bean
KE, Guize L. Should diastolic and systolic blood pressure considered
for cardiovascular risk evaluation: a study in middle-aged men and women.
J Am Coll Cardiol 2001; 37: 163-8.
25) Staessen JA, Gasowski J, Wang JG,
Thijs L, Den Hond E, Boissel JP, et al. Risks of untreated and treated
isolated systolic hypertension in the elderly: meta-analysis of outcome
trials. Lancet 2000; 355: 865-72.
26) Kannel WB, D'Agostino PB, Silbershatz
H. Blood pressure and cardiovascular morbidity and mortality rates in
the elderly. Am Heart J 1997; 134: 758-63.
27) Boshuizen HC, Izaks GJ, van Buuren
S, Ligthart GJ. Blood pressure and mortality in elderly people aged
85 and older: community based study. BMJ 1998; 316: 1780-4.
28) Shea S, Cook EF, Kannel WB, Goldman
L. Treatment of hypertension and its effect on cardiovascular risk factors:
data from the Framingham Heart Study. Circu-lation 1985: 71: 22-30.
29) Mosterd A, D'Agostino PB, Silbershatz
H, Sytkowski PA, Kannel WB, Grobee DE, et al. Trends in the prevalence
of hypertension, antihypertensive therapy, and left ventricular hypertrophy
from 1950 to 1989. N Engl J Med 1999; 340: 1221-7.
30) Sytkowski PA, D'Agostino RB, Belanger
AJ, Kannel WB. Secular trends in long-term sustained hyperten-sion,
long-term treatment, and cardiovascular morta-lity: the Framingham Heart
Study 1950-1990. Circula-tion 1996; 93: 697-703.
31) D'Agostino RB, Wolf PA, Belanger
AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive
medication: the Framingham Study. Stroke 1994; 25: 40-3.
32) The Joint National Committee on Prevention,
Detection, Evaluation, and Treatment of High Blood Pressure, the National
High Blood Pressure Education Program Coordinating Committee: the sixth
report of the Joint National Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413-46.
33) Lloyd-Jones DM, Evans JC, Larson
MG, O'Donnell CJ, Roccella EJ, Levy D. Differential control of systolic
and diastolic blood pressure: factors associated with lack of blood
pressure control in the community. Hypertension 2000; 36: 594-9.
34) Abascal VM, Larson MG, Evans JC,
Blohm AT, Poli K, Levy D. Calcium antagonists and mortality risk in
men and women with hypertension in the Framingham Heart Study. Arch
Intern Med 1998; 158: 1882-6.
35) Gillman MW, Kannel WB, Belanger A,
D'Agostino RB. Influence of heart rate on mortality among persons with
hypertension: the Framingham Study. Am Heart J 1993; 125: 1148-54.
36) Thomas F, Bean K, Provost JC, Guize
L, Benetos A. Combined effects of heart rate and pulse pressure on cardiovascular
mortality according to age. J Hypertens 2001; 19: 863-9.
37) Tsuji H, Venditti FJ Jr, Manders
ES, Evans JC, Larson MG, Feldman CL, et al. Reduced heart rate variability
and mortality risk in an elderly cohort: the Framingham Heart Study.
Circulation 1994; 90: 878-83.
38) Singh JP, Larson MG, O'Donnell CJ,
Wilson PF, Tsuji H, Lloyd-Jones DM, et al. Association of hyperglycemia
with reduced heart rate variability (The Framingham Heart Study). Am
J Cardiol 2000; 86: 309-12.
39) Kannel WB. Hypertension: relationship
with other risk factors. Drugs 1986; 31(Suppl 1): S1-11.
40) Levy D, Gsrrison RJ, Savage DD, Kannel
WB, Castelli WP. Prognostic implications of echocardiographically determined
left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;
322: 1561-6.
41) Krumholz HM, Larson M, Levy D. Prognosis
of left ventricular geometric patterns in the Framingham Heart Study.
J Am Coll Cardiol 1995; 25: 879-84.
42) Verdecchia P, Schillaci G, Borgioni
C, Ciucci A, Battistelli M, Bartoccino C, et al. Adverse prognostic
significance of concentric remodeling of the left ventri-cle in hypertensive
patients with normal left ventricular mass. J Am Coll Cardiol 1995;
25: 871-8.
43) Bikkina M, Levy D, Evans JC, Larson
MG, Benjamin EJ, Wolf PA, et al. Left ventricular mass and risk of stroke
in an elderly cohort: the Framingham Heart Study. JAMA 1994; 272: 33-6.
44) Levy D, Salomon M, D'Agostino RB,
Belanger AJ, Kannel WB. Prognostic implications of baseline electro-cardiographic
features and their serial changes in sub-jects with left ventricular
hypertrophy. Circulation 1994; 90: 1786-93.
45) Benjamin EJ, Levy D. Why is left
ventricular hyper-trophy so predictive of morbidity and mortality? Am
J Med Sci 1999; 317: 168-75.
46) Lauer MS, Anderson KM, Kannel WB,
Levy D. The impact of obesity on left ventricular mass and geometry
the Framingham Heart Study. JAMA 1991; 266: 231-6.
47) Manolio TA, Levy D, Garrison RJ,
Castelli WP, Kannel WB. Relation of alcohol intake to left ventricular
mass: the Framingham Study. J Am Coll Cardiol 1991; 17: 717-21.
48) Stokes J�｡, Kannel WB, Wolf PA, Cupples
LA, D'Agostino PB. The relative importance of selected risk factors
for various manifestations of cardiovascular dis-ease among men and
women from 35 to 64 years old: 30 years of follow-up in the Framingham
Study. Circulation 1987; 75(Suppl V): S65-73.
49) Strasser T. Equal blood pressure
levels carry different risk in different risk factor combinations. J
Hum Hyper-tens 1992; 6: 261-4.
50) Gordon T, Castelli WP, Hjortland
MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor
against coronary heart disease: the Framingham Study. Am J Med 1977;
62: 707-14.
51) Castelli WP. Cholesterol and lipids
in the risk of coronary artery disease: the Framingham Heart Study.
Can J Cardiol 1988; 4(Suppl A): S5-10.
52) Lipid Research Clinics Program: the
Lipid Research Clinics Coronary Primary Prevention Trial results. II.
The relationship of reduction in incidence of coronary heart disease
to cholesterol lowering. JAMA 1984; 251: 365-74.
53) Seman LJ, DeLuca C, Jenner JL, Cupples
LA, McNamara JR, Wilson PWF, et al. Lipoprotein(a)-cholesterol and coronary
heart disease in the Framin-gham Heart Study. Clin Chem 1999; 45: 1039-46.
54) Gordon T, Castelli WP, Hojortland
MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity
in coronary heart disease risk for women:the Framingham study. Ann Intern
Med 1977; 87: 393-7.
55) Siegel RD, Cupples A, Schaefer EJ,
Wilson PW. Lipoproteina, apolipoproteins, and low-density lipopro-tein
size among doabetics in the Framingham offspring study. Metabolism 1996;
45: 1267-72.
56) Nygard O, Nordrehaug JE, Refsum H,
Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality
in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
57) Bostom AG, Silbershatz H, Rosenberg
IH, Selhub J, D'Agostino RB, Wolf PA, et al. Nonfasting plasma total
homocysyeine levels and all-cause and cardiovascular disease mortality
in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-80.
58) Bostom AG, Rosenberg IH, Silbershatz
H, Jacques PF, Selhub J, D'Agostino RB, et al. Nonfasting plasma total
homocysyeine levels and stroke incidence in elderly persons: the Framingham
Study. Ann Intern Med 1999; 131: 352-5.
59) Wong ND, Cupples LA, Ostfeld AM,
Levy D, Kannel WB. Risk factors for long-term coronary prognosis after
initial myocardial infarction: the Framingham study. Am J Epidemiol
1989; 130: 469-80.
60) D'Agostino PB, Belanger A, Kannel
WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary
heart death in the presence of myocardial infarction: the Framingham
study. BMJ 1991; 303: 385-9.
61) Furberg CD, Psaty BM, Manolio TA,
Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation
in elderly subjects (the Cardiovascular Health Study). Am J Med 1994;
74: 236-41.
62) Kannel WB, Wolf PA, Benjamin EJ,
Levy D. Prevalence, incidence, prognosis, and predisposing conditions
for atrial fibrillation: population-based estimates. Am J Cardiol 1998;
82(Suppl 8A): S2-9.
63) Yusuf S, Throm T, Abbott RD. Changes
in hypertension treatment and in congestive heart failure in United
States. Hypertension 1989; 13(Suppl I): S74-9.
64) Levy D, Larson MG, Vasan RS, Kannel
WB, Ho KLL. The progression from hypertension to congestive heart failure.
JAMA 1996; 275: 1557-62.
65) Vasan RS, Levy D. The role of hypertension
in the pathogenesis of heart failure: a clinical mechanistic overview.
Arch Intern Med 1996; 156: 1789-96.
66) Kannel WB. Framingham study insights
into hyperten-sive risk of cardiovascular disease. Hypertens Res 1996;
18: 181-96.
67) Chen YT, Vaccarino V, Williams CS,
Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in
the elderly: a prospective community-based study. Am J Med 1999; 106:
606-12.
68) Vasan RS, Larson MG, Benjamin EJ,
Evans JC, Levy D. Left ventricular dilation and the risk of congestive
heart failure in people without myocardial infarction. N Engl J Med
1997; 336: 1350-5.
69) Vasan RS, Larson MG, Benjamin EJ,
Evans JC, Reiss CK, Levy D.Congestive heart failure in subjects with
normal versus reduced left ventricular ejection fraction: prevalence
and mortality in a population based cohort. J Am Coll Cardiol 1999;
33: 1948-55.
70) Lloyd-Jones DM. The risk of congestive
heart failure: sobering lessons from the Framingham Heart Study. Curr
Cardiol Reprts 2001; 3: 184-90.
71) Goldberg RJ, Larson M, Levy D. Factors
associated with survival to 75 years of age in middle-aged men and women.
Arch Intern Med 1996; 156: 505-9.
72) Visser M, Harris TB, Langlois J,
Hannan MT, Roubenoff R, Felson DT, et al. Body fat and skeletal muscle
mass in relation to physical disability in very old men and women of
the Framingham Heart Study. J Gerontol A Biol Sci Med Sci 1998; 53:
M214-21.
73) Gordon T, Kannel WB. Drinking and
its relation to smoking, BP, blood lipids, and uric acid: the Framing-ham
study. Arch Intern Med 1983; 143: 1366-74.
74) Elias PK, Elias MF, D'Agostino RB,
Silbershatz H, Wolf PA. Alcohol consumption and cognitive performance
in the Framingham Heart Study. Am J Epidemiol 1999; 150: 580-9.
75) Djousse L, Levy D, Murabito JM, Cupples
LA, Ellison RC. Alcohol consumption and risk of intermittent claudication
in the Framingham Heart Study. Circulation 2000; 102: 3092-7.
76) Felson DT, Zhang Y, Hannan MT, Kannel
WB, Kiel DP. Alcohol intake and bone mineral density in elderly men
and women: the Framingham Study. Am J Epidemiol 1995; 42: 485-92.
77) Gordon T, Kannel WB. Drinking and
mortality: the Framingham Study. Am J Epidemiol 1984; 120: 97-107.
78) WHO Expert Committee. Hypertension
control. Report of a WHO Expert Committee. World Health Organi-zation
Technical Report Series 862; 1996. p.1-83.
79) Guidelines Subcommittee. 1999 World
Health Organiza-tion-International Society of Hypertension Guidelines
for the Management of Hypertension. J Hypertens 1999; 17: 151-83.
80) Ramsey LE, Williams B, Johnston GD,
MacGregor GA, Poston L, Potter JF, et al. Guidelines for management
of hypertension: report of the third working party of the British Hypertension
Society. J Hum Hypertens 1999; 13: 569-92.
81) European Society of Cardiology, European
Atherosclero-sis Society, European Society of Hypertension, Interna-tional
Society of Behavoural Medicine, European Socie-ty of General Practice/Family
Medicine, European Heart Network. Prevention of coronary heart diseasein
clinical Practice: recommendations of the Second Joint Task Force of
European and other Societies of Coronary Prevention. Eur Heart J 1998;
19: 1434-503.
82) Goldstein LB, Adams R, Becker K,
Furberg CD, Gorelick PB, Hademenos G, et al. Primary prevention of ischemic
stroke: a steatement for healthcare pro-fessionals from the Stroke Council
of the American Heart Association. Circulation 2001; 103: 163-82.
83) D'Agostino RB, Wolf PA, Belanger
AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive
medication: the Framingham Study. Stroke 1994; 25: 40-3.
84) Ogden LG, He J, Lydick E, Whelton
PK. Long-term absolute benefit of lowering blood pressure in hyper-tensive
patients according o the JNC VI risk stratifi-cation. Hypertension 2000;
35: 539-43.
85) Lloyd-Jones DM, Evans JC, Larson
MG, O'Donell CJ, Wilson PW, Levy D. Cross-classification of JNC VI blood
pressure stages and risk groups in the Framing-ham Heart Study. Arch
Intern Med 1999; 159: 2206-12.
|
